Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 7/20 | 0.37 |
| ▸ | HTR2A | P28223 | 6/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10100582 | 0.93 | ADORA2A (0.39) | ADORA2AADORA1FYNHTR2CHTR2A | |
| SCHEMBL10100720 | 0.93 | MCHR1 (0.40) | FYNHTR2CMCHR1SMN1; SMN2ESR1 | |
| SCHEMBL10100778 | 0.93 | LRRK2 (0.42) | ADORA2AADORA1FYNHTR2APIK3R1 | |
| SCHEMBL10100717 | 0.93 | HRH3 (0.36) | FYNMCHR1PIK3R1PIK3CATLR7 | |
| SCHEMBL10100767 | 0.92 | MCHR1 (0.40) | FYNHTR2CHTR2AHTR2BMCHR1 | |
| SCHEMBL10100711 | 0.92 | BMPR1B (0.37) | FYNHTR2CHTR2AHTR2BMCHR1 | |
| SCHEMBL10100724 | 0.92 | SMN1; SMN2 (0.37) | HTR2CHTR2AHTR2BPIK3R1PIK3CA | |
| SCHEMBL10100716 | 0.92 | ABL1 (0.36) | HTR2CHTR2AHTR2BPIK3R1PIK3CA | |
| SCHEMBL10100709 | 0.91 | SMN1; SMN2 (0.38) | HTR2CHTR2AHTR2BPIK3R1PIK3CA | |
| SCHEMBL10100715 | 0.90 | FYN (0.41) | FYNHTR2CHTR2AMCHR1TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | ADORA2A 2697/4885ADORA1 3435/4885FYN 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.